Annual report pursuant to Section 13 and 15(d)

Segment reporting (Details) - Schedule of segment reporting information, by segment

v3.20.2
Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($)
$ in Thousands
12 Months Ended
Jul. 31, 2020
Jul. 31, 2019
Jul. 31, 2018
Clinical Labs [Member]      
Segment Reporting Information [Line Items]      
Revenues – Services and Products $ 47,964 $ 51,115 $ 71,077
Grant income 1,496    
Total 49,460    
Cost of revenues 38,855 44,226 46,008
Research and development 1,509 31
Selling, general and administrative 23,533 24,230 24,656
Legal and related expenses 211 159 67
Legal settlements, net    
Total operating costs, expenses and legal settlements, net 64,108 68,646 70,731
Operating (loss) income (14,648) (17,531) 346
Interest (36) (64) (91)
Other 45 16 29
Foreign exchange gain (loss)
Income (loss) before taxes (14,639) (17,579) 284
Depreciation and amortization included above 1,553 1,625 1,667
Capital expenditures 1,811 1,374 1,685
Life Sciences [Member]      
Segment Reporting Information [Line Items]      
Revenues – Services and Products 26,561 30,055 29,936
Grant income    
Total 26,561    
Cost of revenues 13,396 13,696 14,377
Research and development 2,190 2,257 2,305
Selling, general and administrative 10,485 11,860 11,617
Legal and related expenses 2 27 58
Legal settlements, net   (28,925)  
Total operating costs, expenses and legal settlements, net 26,073 (1,085) 28,357
Operating (loss) income 488 31,140 1,579
Interest 56 67 50
Other 13 2 11
Foreign exchange gain (loss) 905 (682) (275)
Income (loss) before taxes 1,462 30,527 1,365
Depreciation and amortization included above 964 1,221 1,387
Capital expenditures 322 605 203
Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Revenues – Services and Products
Grant income    
Total    
Cost of revenues
Research and development 749 887 905
Selling, general and administrative
Legal and related expenses
Legal settlements, net    
Total operating costs, expenses and legal settlements, net 749 887 905
Operating (loss) income (749) (887) (905)
Interest
Other
Foreign exchange gain (loss)
Income (loss) before taxes (749) (887) (905)
Depreciation and amortization included above
Capital expenditures
Other Segments [Member]      
Segment Reporting Information [Line Items]      
Revenues – Services and Products
Grant income    
Total    
Cost of revenues
Research and development
Selling, general and administrative 8,942 8,175 8,182
Legal and related expenses 6,516 2,814 5,002
Legal settlements, net    
Total operating costs, expenses and legal settlements, net 15,458 10,989 13,184
Operating (loss) income (15,458) (10,989) (13,184)
Interest 434 1,053 894
Other 430 364 128
Foreign exchange gain (loss)
Income (loss) before taxes (14,594) (9,572) (12,162)
Depreciation and amortization included above 263 190 76
Capital expenditures 37 6,147
Consolidated [Member]      
Segment Reporting Information [Line Items]      
Revenues – Services and Products 74,525 81,170 101,013
Grant income 1,496    
Total 76,021    
Cost of revenues 52,251 57,922 60,385
Research and development 4,448 3,175 3,210
Selling, general and administrative 42,960 44,265 44,455
Legal and related expenses 6,729 3,000 5,127
Legal settlements, net   (28,925)  
Total operating costs, expenses and legal settlements, net 106,388 79,437 113,177
Operating (loss) income (30,367) 1,733 (12,164)
Interest 454 1,056 853
Other 488 382 168
Foreign exchange gain (loss) 905 (682) (275)
Income (loss) before taxes (28,520) 2,489 (11,418)
Depreciation and amortization included above 2,780 3,036 3,130
Capital expenditures 2,170 8,126 1,888
Selling, general and administrative [Member] | Clinical Labs [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 57 147 125
Selling, general and administrative [Member] | Life Sciences [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 74 95 79
Selling, general and administrative [Member] | Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation
Selling, general and administrative [Member] | Other Segments [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 756 697 609
Selling, general and administrative [Member] | Consolidated [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 887 939 813
Cost of Sales [Member] | Clinical Labs [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 46    
Cost of Sales [Member] | Life Sciences [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation    
Cost of Sales [Member] | Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation    
Cost of Sales [Member] | Other Segments [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation    
Cost of Sales [Member] | Consolidated [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 46    
Total [Member] | Clinical Labs [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 103 147 125
Total [Member] | Life Sciences [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 74 95 79
Total [Member] | Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation
Total [Member] | Other Segments [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 756 697 609
Total [Member] | Consolidated [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation $ 933 $ 939 $ 813